# 1. Financial Performance ## A. Key Figures * **Gross Profit Margin:** **60.8%** FY26 (+747 bps) · **62.9%** H2FY26 * **EBITDA:** **₹98.1 Cr** FY26 (+39%) · **₹62.1 Cr** H2FY26 (+39%) * EBITDA Margin: **28.7%** FY26 (+616 bps) · **31.4%** H2FY26 * **EPS:** **₹35.41** FY26 (vs. ₹22.97 FY25) · **₹22.10** H2FY26 ## B. Revenue & Margin Expansion * **Headline: Sustained Multi-Year Growth:** The company delivered a robust three-year revenue CAGR, with top-line performance nearly doubling since FY23 despite a slight softening in the second half of the current fiscal. * **Headline: Structural Margin Uplift:** Significant expansion in gross and EBITDA margins driven by a shift toward high-margin domestic reagent manufacturing, favorable product mix, and enhanced operating efficiencies. * **Headline: Value-Added Strategy:** Profitability gains are increasingly supported by higher value addition and strategic investments in innovation and product development. ## C. Profitability Metrics * **Headline: Strong Bottom-Line Recovery:** Net profit saw triple-digit growth in FY26, rebounding sharply from a prior-year dip caused by a **₹22.7 Cr** extraordinary item. * **Headline: Improving Return Profile:** ROE recovered to high-twenties levels in FY26, while ROCE remained stable at **19%**, reflecting efficient capital deployment following a volatile FY25. * **Headline: Rising Operational Costs:** Growth is accompanied by a significant increase in employee and other operating expenses, alongside rising depreciation and finance costs as the business scales. ## D. Balance Sheet * **Headline: Asset Base Expansion:** The consolidated balance sheet more than doubled over three years, fueled by a near-tripling of non-current assets to **₹214.6 Cr** through heavy investment in PPE and intangibles. * **Headline: Increased Leverage for Growth:** Net worth expanded to **₹246.2 Cr**, though the Debt-to-Equity ratio rose to **0.92x** as long-term and short-term borrowings increased to fund expansion. * **Headline: Working Capital Dynamics:** Trade receivables and cash reserves have scaled with the business, while inventory levels have stabilized at **₹95.0 Cr** following a peak in FY24. --- # 2. Manufacturing & Capacity ## A. Key Figures * **Unit 2 (Lucknow) Capacity:** **96,000 kits** Installed · **67%** Utilization * **Unit 3 (Lucknow) Capacity:** **1,200 analyzers** Installed · **57%** Utilization * **Capital Works-in-Progress (CWIP):** **₹62.55 Cr** peak (Mar-25) · **₹19.31 Cr** projected (Mar-26) ## B. Facility Utilization & Scaling * **Transformative Expansion:** FY26 marked a pivot point with the capitalization of the company’s largest facility in Lucknow, significantly boosting production headroom. * **Unit 4 Activation:** The newly commissioned facility has secured licenses for five products; commercial production for reagents is slated for **Q2 FY27** following regulatory nods. * **Strategic CDMO Pivot:** Capacity scaling is specifically aligned with the "Make in India" initiative to support both proprietary reagents and the burgeoning CDMO business segment. ## C. Unit Capitalization * **Capex Cycle Completion:** The sharp projected decline in CWIP by March 2026 signals the transition from heavy investment to the operationalization of major infrastructure projects. ## D. Localization Progress * **Import Substitution:** Strategic global partnerships have enabled the domestic production of over **50%** of laboratory equipment, directly enhancing margin profiles. * **R&D Pipeline:** Leveraging PLI Scheme tailwinds, the company has one instrument commercialized and **seven devices** currently under development to further reduce import reliance. * **Technical Collaboration:** Successful commercial scaling of the Selectra Pro M analyzer demonstrates the company's ability to localize complex European technical designs for the Indian market. --- # 3. Product & Segment Performance ## A. Key Figures * **Revenue Mix:** **69.8%** Reagents · **24.3%** Diagnostic Instruments · **5.1%** Consumables · **0.8%** Services * **Reagent Sales:** **₹131.5 Cr** FY23 · **₹238.5 Cr** FY26 Proj. (+81% over period) * **Instrument Revenue:** **₹39.1 Cr** FY23 · **₹56.7 Cr** FY24 (+45%) · **₹114.9 Cr** FY25 Proj. * **Service Revenue:** **₹1.77 Cr** FY23 · **₹5.07 Cr** FY24 (+186%) ## B. Reagent Consumables * **Strategic Manufacturing Pivot:** Robust growth in manufactured reagents—which surged **nearly 70%**—reflects a deliberate shift away from lower-margin traded products toward in-house production. * **Recurring Revenue Anchor:** Reagents represent the core business driver, providing a stable, high-margin recurring base fueled by essential IVD testing across Clinical Chemistry, Haematology, and Immunodiagnostics. * **Market Dominance:** The segment maintains a commanding **66%** market share in the broader IVD space, benefiting from the increasing prevalence of chronic diseases and the rise of point-of-care (POC) testing. ## C. Diagnostic Instruments * **Flagship Scaling:** The installed base for the **Selectra Pro M** has exceeded **1,550 units**, with domestic manufacturing of this key asset commencing in late 2023 to optimize the supply chain. * **Portfolio Diversification:** Revenue is scaling through a mix of proprietary and traded analyzers; the company is expanding into three new categories: Immunodiagnostics, Clinical Chemistry, and Haematology. * **Next-Gen Development:** Pipeline visibility is high with the **Selectra Pro XL** (large labs) and **Microlab 300** (semi-auto) under development to capture broader laboratory tiers. ## D. Service Maintenance * **Value-Added Integration:** While currently the smallest revenue contributor, the service arm provides critical annual maintenance and software support, representing a **9%** total market share opportunity. * **Digital Evolution:** Future service growth is tied to the integration of **AI and data analytics** for result interpretation and digital health support. ## E. R&D Pipeline * **Innovation Engine:** The dedicated R&D division focuses on reverse engineering and domestic innovation, currently managing **15+ registered trademarks** and a commercialization roadmap through FY27. * **Upcoming Launches:** Following the successful commercialization of the **InnoLyte** electrolyte analyzer, the **Microlab 300** is slated for a **Q2 FY27** market entry. --- # 4. Market & Geography Mix ## A. Key Figures * **IVD Market Share (CY25):** **38%** Hospital Labs · **30%** Clinical Labs · **13%** POCT · **10%** Self-Testing ## B. Regional Concentration & Distribution * **Strategic Diversification:** While revenue remains heavily anchored in the North, the company is actively diversifying into South, East, and West zones to balance its geographic footprint. [15, 17] * **Nationwide Infrastructure:** Maintains a pan-India reach across **26 states and 2 UTs** supported by **4 manufacturing units** serving labs, hospitals, and medical colleges. [10, 17] * **Public Sector Tailwinds:** Leveraging government initiatives like the National Healthcare Mission and Ayushman Bharat to penetrate rural markets via upgraded health centers. ## C. Export Expansion * **Aggressive International Outlook:** Management expects a **~5x growth** in export turnover for FY27, supported by a new Dubai-based leadership appointment and distributor ties in **7-8 countries**. * **Global Footprint:** Initial international sales have commenced across Africa, the Middle East, and the Indian sub-continent, targeting both general trade and corporate lab chains. [17, 19] ## D. Customer Segments * **Dominant Channels:** Hospital and clinical laboratories remain the primary revenue drivers, collectively controlling over two-thirds of the addressable IVD market. * **Emerging Trends:** Significant market shift toward decentralized diagnostics, with Point-of-Care (POCT) and patient self-testing now representing nearly **one-fourth** of total market demand. --- # 5. Strategic Initiatives ## A. Key Figures * **IPO Proceeds:** **₹214.48 Cr** NSE SME Listing (May 29, 2026) * Equity Issuance: 62,53,000 Fresh Shares * **CDMO Client Base:** **3** EOL Component Clients ## B. CDMO Operations & Competitive Moat * **Strategic Pivot to CDMO:** Launching export-oriented manufacturing for Selectra Pro M and Microlab 300 instruments under exclusive technical collaborations. * **Integrated Platform Advantage:** End-to-end capabilities across reagents, instruments, and consumables create a high-barrier moat and drive domestic cross-selling. * **Cost Leadership:** Positioning as a full-service IVD partner by leveraging manufacturing cost advantages and specialized sourcing of End-of-Life (EOL) components. ## C. Technology Partnerships * **Global-Local Arbitrage:** International technology transfers with European partners enable the production of high-spec platforms (Selectra, Medonic) at competitive Indian price points. * **Diversified Portfolio:** Strategic tie-ups provide comprehensive solutions across Clinical Chemistry, Haematology, Molecular Diagnostics, and Rapid Testing. ## D. Digital Transformation & Capital Allocation * **Operational Efficiency:** Enterprise-wide digital transformation via ERP implementation is underway, with full rollout targeted for **FY27-end**. * **Utilization of Funds:** Capital raised via the recent listing is earmarked for working capital, debt repayment, and general corporate scaling. --- # 6. Risks & Regulatory Factors ## A. Key Figures * **India IVD Market Size:** **$2,141M** 2021 Peak · **$1,307M** 2023 Normalized ## B. Compliance & Governance * **Framework Strengthening:** Engaging **PwC** to enhance internal controls (IFC and ICFR), signaling a move toward more robust institutional governance. * **Regulatory Oversight:** Manufacturing facilities maintain multi-agency compliance across domestic (CDSCO) and international (European) bodies, including mandatory post-market surveillance for IVD devices. * **Policy Tailwinds:** Leveraging the **PLI Scheme** for high-end diagnostics and **ICMR** support for indigenous innovation to reduce import dependency. ## C. Approval Complexity & R&D Pipeline * **Product Development Hurdles:** Navigating a complex CDSCO approval landscape for high-risk devices; the **Medonic M20** and **KCI Del** (Stago partnership) are currently in regulatory review. * **Indigenous Innovation:** The **Q-Count 5** 5-part analyzer remains in the development phase as the company seeks to localize high-end hematology technology. ## D. Supply Chain & Market Dynamics * **Global Dependencies:** Operations remain sensitive to international supply chain stability for critical raw materials and component procurement. * **Post-Pandemic Normalization:** The domestic market has undergone a significant correction following the unsustainable pandemic-era surge, stabilizing at lower volume levels. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Target:** **30% to 35%** YoY for FY27 * **Projected Net Revenue:** **₹341.74 Cr** by FY26 (from ₹182.74 Cr in FY23) (**23% CAGR**) * **Indian IVD Market Growth:** **12.5% CAGR** · **$2,978M** valuation by 2030 (from $1,512M in 2024) ## B. Revenue Targets & Growth Projections * **Aggressive Top-line Expansion:** Management anticipates robust double-digit annual growth through FY27, significantly outperforming the broader market CAGR. * **Industry Tailwinds:** Growth is underpinned by technological innovation, a rising geriatric demographic, and the increasing adoption of cost-efficient diagnostic solutions. ## C. Market Opportunity * **Disease Burden Driving Demand:** Rising prevalence of chronic conditions (diabetes, cancer) and infectious diseases (TB, dengue) positions IVD as a critical healthcare pillar. * **Demographic Momentum:** India’s expanding population and increased life expectancy are creating a sustained upward trajectory for diagnostic solution volume. * **Historical Context:** The domestic market has shown consistent scaling, nearly doubling in value between **2019 ($1,237M)** and **2022 ($1,933M)**. ## D. Strategic Roadmap * **Portfolio Expansion:** Execution is focused on a deep development roadmap aligned with the **"Make in India"** initiative to capture a larger share of the total addressable market.